GT Biopharma (GTBP) Competitors $2.78 -0.32 (-10.16%) Closing price 07/3/2025 03:25 PM EasternExtended Trading$2.78 -0.01 (-0.36%) As of 07/3/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GTBP vs. MRSN, ARTV, ELYM, XLO, ATHE, LVTX, LTRN, CLNN, RNTX, and KZRShould you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include Mersana Therapeutics (MRSN), Artiva Biotherapeutics (ARTV), Eliem Therapeutics (ELYM), Xilio Therapeutics (XLO), Alterity Therapeutics (ATHE), LAVA Therapeutics (LVTX), Lantern Pharma (LTRN), Clene (CLNN), Rein Therapeutics (RNTX), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry. GT Biopharma vs. Its Competitors Mersana Therapeutics Artiva Biotherapeutics Eliem Therapeutics Xilio Therapeutics Alterity Therapeutics LAVA Therapeutics Lantern Pharma Clene Rein Therapeutics Kezar Life Sciences Mersana Therapeutics (NASDAQ:MRSN) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Does the media favor MRSN or GTBP? In the previous week, Mersana Therapeutics had 2 more articles in the media than GT Biopharma. MarketBeat recorded 3 mentions for Mersana Therapeutics and 1 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 0.00 beat Mersana Therapeutics' score of -0.63 indicating that GT Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mersana Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate MRSN or GTBP? Mersana Therapeutics currently has a consensus target price of $5.20, indicating a potential upside of 1,693.10%. GT Biopharma has a consensus target price of $11.00, indicating a potential upside of 294.97%. Given Mersana Therapeutics' higher possible upside, equities analysts clearly believe Mersana Therapeutics is more favorable than GT Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has higher valuation and earnings, MRSN or GTBP? GT Biopharma has lower revenue, but higher earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$40.50M0.89-$69.19M-$0.59-0.49GT BiopharmaN/AN/A-$13.16M-$5.69-0.49 Is MRSN or GTBP more profitable? GT Biopharma has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -217.63%. Mersana Therapeutics' return on equity of -990.16% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-217.63% -990.16% -48.87% GT Biopharma N/A -1,033.08%-223.20% Which has more risk & volatility, MRSN or GTBP? Mersana Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Do insiders and institutionals have more ownership in MRSN or GTBP? 93.9% of Mersana Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 13.0% of Mersana Therapeutics shares are owned by insiders. Comparatively, 3.4% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryMersana Therapeutics beats GT Biopharma on 9 of the 15 factors compared between the two stocks. Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTBP vs. The Competition Export to ExcelMetricGT BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.23M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-0.4921.5627.5220.22Price / SalesN/A281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book-3.717.518.045.67Net Income-$13.16M-$55.05M$3.18B$249.13M7 Day Performance-21.33%4.61%2.90%3.28%1 Month Performance3.15%4.72%3.70%5.56%1 Year Performance-1.94%5.92%36.15%21.12% GT Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTBPGT Biopharma1.4356 of 5 stars$2.79-10.2%$11.00+295.0%+1.3%$7.23MN/A-0.498MRSNMersana Therapeutics3.6658 of 5 stars$0.30+1.7%$5.20+1,656.8%-84.2%$36.27M$40.50M-0.50150News CoverageARTVArtiva Biotherapeutics2.2509 of 5 stars$1.51+2.7%$17.80+1,078.8%N/A$35.81M$250K0.0081Gap UpELYMEliem TherapeuticsN/A$1.18-6.3%N/A-81.3%$35.11MN/A-2.239High Trading VolumeXLOXilio Therapeutics2.7517 of 5 stars$0.68+0.7%$4.00+488.3%-19.7%$34.97M$6.34M-0.8170News CoveragePositive NewsATHEAlterity Therapeutics2.6533 of 5 stars$4.09+4.1%$12.00+193.4%+122.3%$34.88MN/A0.0010LVTXLAVA Therapeutics1.8368 of 5 stars$1.32+0.8%$3.17+139.9%-25.8%$34.46M$11.98M-1.2760LTRNLantern Pharma2.481 of 5 stars$3.16-0.9%$25.00+691.1%-25.9%$34.40MN/A-1.7220News CoverageGap DownCLNNClene2.2987 of 5 stars$3.91+4.0%$40.00+923.0%-39.9%$33.78M$340K-0.97100News CoverageRNTXRein TherapeuticsN/A$1.40-4.8%N/AN/A$32.57MN/A-0.499Gap UpHigh Trading VolumeKZRKezar Life Sciences4.2067 of 5 stars$4.58+3.2%$39.50+762.4%-21.3%$32.44M$7M-0.4260 Related Companies and Tools Related Companies Mersana Therapeutics Alternatives Artiva Biotherapeutics Alternatives Eliem Therapeutics Alternatives Xilio Therapeutics Alternatives Alterity Therapeutics Alternatives LAVA Therapeutics Alternatives Lantern Pharma Alternatives Clene Alternatives Rein Therapeutics Alternatives Kezar Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GTBP) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GTBP Stock Alerts